Integral Investment Advisors Inc. Acquires 593 Shares of Zoetis Inc. (NYSE:ZTS)

Integral Investment Advisors Inc. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 19.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,585 shares of the company’s stock after purchasing an additional 593 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Zoetis were worth $590,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Mission Wealth Management LP raised its stake in Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares during the last quarter. VeraBank N.A. boosted its holdings in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after buying an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC grew its holdings in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock worth $68,000 after purchasing an additional 64 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its position in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 3.2%

Zoetis stock opened at $164.65 on Tuesday. The firm has a 50 day moving average price of $157.43 and a 200-day moving average price of $164.12. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a market capitalization of $73.30 billion, a P/E ratio of 30.10, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period last year, the business posted $1.38 earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis’s dividend payout ratio is 35.91%.

Analyst Ratings Changes

A number of brokerages have commented on ZTS. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler upped their price target on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. Finally, Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $212.75.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.18% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.